We manufacture and market a large basket of pharmaceutical formulations across chronic and acute therapies, including generics, branded generics, specialty & complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Our portfolio spans multiple dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. With billions of doses delivered annually across our key therapeutic areas like neuro-psychiatry, cardiology, gastroenterology, anti-infectives diabetology, oncology, ophthalmology, dermatology, urology, nephrology, respiratory, and more, we are helping improve access to medicine globally.

The first among Indian pharmaceutical companies to realise and embrace the importance of innovation, we invest 6–8% of global revenues annually into Research and Development (R&D). With a team of over 3,000 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development, our strength lies in developing generics and technologically complex products. We specialize in differentiated products including liposomal drugs, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms, showcasing our strong focus on innovation.

From humble beginnings in 1983, Sun Pharma has grown into a leading specialty generic company worldwide and the No. 1 pharmaceutical company in India. In the U.S., we are amongst the leading specialty generic companies and are ranked No. 2 in generic dermatology by prescriptions.  We have a presence in 80 countries across emerging markets, with  Brazil, Mexico, Russia, Romania, and South Africa being some of the key markets.  We maintain a strong footprint across Western Europe, Canada, Australia, New Zealand, Israel and Japan.